Why the study?
Does sulfinpyrazone or aspirin/dipyridamole improve platelet survival time and beta-thromboglobulin levels in patients with angiographically documented coronary artery disease?
Population
48 patients with angiographically documented coronary artery disease (CAD)
Comparison
Sulfinpyrazone or aspirin/dipyridamole vs Placebo (crossover design)
Design
RCT, double-blind
Authors
Loading...
No effect on platelet markers in CAD; challenges presumed mechanism and utility of these agents.
Does sulfinpyrazone or aspirin/dipyridamole improve platelet survival time and beta-thromboglobulin levels in patients with angiographically documented coronary artery disease?
In patients with CAD, treatment with sulfinpyrazone or aspirin/dipyridamole had no measurable effect on platelet survival time or beta-thromboglobulin levels compared to placebo.
Boer et al. (1983) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: